A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 inhibitors ... [1] In the presence of elevated glucose concentrations, GLP-1 and GIP increase ...

We have demonstrated that in subjects with IFG, 6 weeks of treatment with the DPP-4 inhibitor vildagliptin ... is that elevated levels of GIP and GLP-1 have direct beneficial effects on β-cell ...

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor.

Despite their remarkable efficacy for many populations, GLP-1s have a relatively low persistence rate over time, due to a combination of ... having taken a GLP-1 already — including 43% of ...

in combination with semaglutide, a GLP-1 agonist marketed by Novo Nordisk (NYSE: NVO) un As the U.S. markets experience mixed results with the S&P 500 and Dow Jones snapping their six-week winning ...

In terms of new products, both Novo Nordisk and Sanofi are set to launch basal insulin/GLP-1 combinations ... 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos ...

Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...

Hello, Health Rounds Readers! Today we feature a study that found yet another potential health benefit of GLP-1 drugs, this ...